Impact of Genetic Targets on Therapy in Head and Neck Squamous Cell Carcinoma

Chapter
Part of the Advances in Experimental Medicine and Biology book series (volume 779)

Abstract

Despite advances in surgical technique, radiation therapy and chemotherapy, the mortality from head and neck squamous cell carcinoma (HNSCC) has not improved significantly. Squamous cell carcinoma is caused by tobacco use, alcohol consumption and infection with high-risk types of human papillomavirus. It is the 6th most common cancer in the world, with upwards of 45,000 new cases reported yearly in the United States alone.

In recent years, there has been a significant increase in the understanding of the molecular and genetic pathogenesis of head and neck cancer, shedding light on the unexpected heterogeneity of the disease. Genetic analysis has led to new classification schemes for HNSCC, with different subgroups exhibiting different prognoses. In addition, multiple targets in aberrant signaling pathways have been identified using increasingly sophisticated bio-informatics tools. Advances in technology have allowed for novel delivery mechanisms to introduce genetic material into cells to produce a therapeutic effect by targeting cancer cells via a number of different approaches.

A pressing need to develop novel therapies to augment current treatment modalities has led to a number of translational studies involving gene therapy in the treatment of HNSCC. This article will focus on a review of the most recent developments in molecular biology of head and neck squamous cell carcinoma in regards to possible targets for gene therapy, as well as the array of novel therapeutic strategies directed at these targets.

Keywords

Gene therapy Head and neck squamous cell carcinoma (HNSCC) Genetic targets HPV P53 

References

  1. 1.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRefGoogle Scholar
  3. 3.
    Sanderson RJ, Ironside JA. Squamous cell carcinomas of the head and neck. BMJ. 2002;325(7368):822–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Howlader N. SEER Cancer Statistics Review, 1975–2008. National Cancer Institute, 2011.Google Scholar
  5. 5.
    Argiris A, et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004;10(6):1956–62.PubMedCrossRefGoogle Scholar
  6. 6.
    Pignon JP, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Lancet. 2000;355(9208):949–55.PubMedGoogle Scholar
  7. 7.
    Gillison ML, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100(6):407–20.PubMedCrossRefGoogle Scholar
  8. 8.
    Kreimer AR, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467–75.PubMedCrossRefGoogle Scholar
  9. 9.
    Pyeon D, et al. Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog. 2009;5(2):e1000318.PubMedCrossRefGoogle Scholar
  10. 10.
    Rampias T, et al. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst. 2009;101(6):412–23.PubMedCrossRefGoogle Scholar
  11. 11.
    Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 2007;121(8):1813–20.PubMedCrossRefGoogle Scholar
  12. 12.
    Wiest T, et al. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene. 2002;21(10):1510–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Poeta ML, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357(25):2552–61.PubMedCrossRefGoogle Scholar
  14. 14.
    Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6(5):963–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Boyle JO, et al. Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. Am J Surg. 1994;168(5):429–32.PubMedCrossRefGoogle Scholar
  16. 16.
    Califano J, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 1996;56(11):2488–92.PubMedGoogle Scholar
  17. 17.
    Mao L, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med. 1996;2(6):682–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Meredith SD, et al. Chromosome 11q13 amplification in head and neck squamous cell carcinoma. Association with poor prognosis. Arch Otolaryngol Head Neck Surg. 1995;121(7):790–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Tabor MP, et al. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res. 2001;7(6):1523–32.PubMedGoogle Scholar
  20. 20.
    Tabor MP, et al. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res. 2004;10(11):3607–13.PubMedCrossRefGoogle Scholar
  21. 21.
    Brennan JA, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995;332(7):429–35.PubMedCrossRefGoogle Scholar
  22. 22.
    van Houten VM, et al. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol. 2002;198(4):476–86.PubMedCrossRefGoogle Scholar
  23. 23.
    Poeta ML, et al. The ligamp TP53 assay for detection of minimal residual disease in head and neck squamous cell carcinoma surgical margins. Clin Cancer Res. 2009;15(24):7658–65.PubMedCrossRefGoogle Scholar
  24. 24.
    Carvalho AL, et al. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res. 2008;14(1):97–107.PubMedCrossRefGoogle Scholar
  25. 25.
    Goldenberg D, et al. Intraoperative molecular margin analysis in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004;130(1):39–44.PubMedCrossRefGoogle Scholar
  26. 26.
    Al-Hajj M, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(7):3983–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Reya T, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–11.PubMedCrossRefGoogle Scholar
  28. 28.
    Prince ME, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 2007;104(3):973–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Clay MR, et al. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck. 2010;32(9):1195–201.PubMedCrossRefGoogle Scholar
  30. 30.
    Krishnamurthy S, et al. Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res. 2010;70(23):9969–78.PubMedCrossRefGoogle Scholar
  31. 31.
    Mani SA, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.PubMedCrossRefGoogle Scholar
  32. 32.
    Perl AK, et al. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998;392(6672):190–3.PubMedCrossRefGoogle Scholar
  33. 33.
    Chung CH, et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappa B signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res. 2006;66(16):8210–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Ang KK, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.PubMedCrossRefGoogle Scholar
  35. 35.
    Roepman P, et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet. 2005;37(2):182–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Maxwell PH, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Tse GM, et al. Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma. Ann Surg Oncol. 2007;14(12):3558–65.PubMedCrossRefGoogle Scholar
  38. 38.
    Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005;11(4):1434–40.PubMedCrossRefGoogle Scholar
  39. 39.
    Hasina R, et al. Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications. Lab Invest. 2008;88(4):342–53.PubMedCrossRefGoogle Scholar
  40. 40.
    Bozec A, et al. Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model. Ann Oncol. 2009;20(10):1703–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Myoung H, et al. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Lett. 2001;163(2):191–200.PubMedCrossRefGoogle Scholar
  42. 42.
    Fountzilas G, et al. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol. 2010;65(4):649–60.PubMedCrossRefGoogle Scholar
  43. 43.
    Choong NW, et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010;28(5):677–83.PubMedCrossRefGoogle Scholar
  44. 44.
    Machiels JP, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006–01. J Clin Oncol. 2010;28(1):21–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Williamson SK, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: southwest oncology group study S0420. J Clin Oncol. 2010;28(20):3330–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Cohen EE, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009;10(3):247–57.PubMedCrossRefGoogle Scholar
  47. 47.
    Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160–74.PubMedCrossRefGoogle Scholar
  48. 48.
    Ang KK, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62(24):7350–6.PubMedGoogle Scholar
  49. 49.
    Chung CH, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004;5(5):489–500.PubMedCrossRefGoogle Scholar
  50. 50.
    Sheikh Ali MA, et al. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci. 2008;99(8):1589–94.PubMedCrossRefGoogle Scholar
  51. 51.
    Vermorken JB, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.PubMedCrossRefGoogle Scholar
  52. 52.
    Bonner JA, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5 year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division Otolaryngology - Head & Neck Surgery, Department SurgeryThe Pennsylvania State University, The Milton S. Hershey Medical CenterHersheyUSA

Personalised recommendations